vaccine ingredients

CEPI is also “in active discussions” with GreenLight Biosciences, which has developed a low-cost cell-free mRNA production method that relies on harvesting nucleotides from yeast biomass.

GreenLight Biosciences and TFF Pharmaceuticals announcement they are to partner on a feasibility arrangement for shelf-stable powder form of messenger RNA COVID-19 Vaccine.

Andrey Zarur, CEO of GreenLight Biosciences, speaks to Vox about the short supply of lipid nanoparticles for Covid-19 vaccines.

GreenLight Biosciences is mentioned in a CNN report on the short supply of key ingredients for Covid-19 vaccines.

Andrey Zarur, CEO of GreenLight Biosciences, spoke to The Washington Post about the scarcity of biotech ingredients

Marta Ortega-Valle, founder of GreenLight Biosciences, talks to Elemental about mRNA and its potential to treat or prevent a whole range of conditions.

Marta Ortega-Valle, founder of GreenLight Biosciences, talks to Elemental about mRNA and its potential to treat or prevent a whole range of conditions in the future. Extracts from the article are below:

“In a way, we can produce medicines inside the body,” says Marta Ortega-Valle, founder of GreenLight, a biotech company that manufactures lab-produced RNA. “We could, instead of manufacturing proteins outside of patients, create them inside the body, using your own cells and the same system your body already has.”…

The vaccines may be the first publicly available pharmaceuticals to use mRNA, but they won’t be the last. Not by a long shot. GreenLight is currently working with the Gates Foundation to develop an mRNA-based treatment for sickle cell anemia. Research has been done into the potential for it to be used as an anti-aging therapy. The list of conditions and diseases that could theoretically be treated or prevented using mRNA vaccines and medicines is long…

Ortega-Valle and many in the science community believe the next frontier of medicine is based in mRNA. And now we’re expected to get there a lot faster. “I think that we’re experiencing an acceleration that was not in the plan,” she says. “My guess is that without the pandemic, a commercial vaccine based on mRNA would have taken many years, if it ever happened. Now we’ve done it, and it opens the door to more.”

Read the full article here.

Find out more about how GreenLight manufactures RNA here.

the FDA had informed the company that it would not need to redo safety trials if all of the vaccine ingredients were the same and only the viral sequence was changed.

It’s likely the company’s drug candidate will act as a second-generation vaccine that could improve upon and supplement products already on the market.

Andrey Zarur, CEO of GreenLight Biosciences, wrote for STAT about the Covid-19 vaccine supply chain.

GreenLight Biosciences spoke to the Financial Times about making sure that any vaccine is new variant ready for Covid-19.

GreenLight Biosciences spoke to the Financial Times about the vaccine supply issues for the Covid-19 vaccine